All Comments by Benjamin Wolozin

  1. Alzheimer's disease: model behaviour.
  2. Protein kinase C regulation of intracellular and cell surface amyloid precursor protein (APP) cleavage in CHO695 cells.
  3. Dementia with Lewy bodies treated with rivastigmine: effects on cognition, neuropsychiatric symptoms, and sleep.
  4. Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression.
  5. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.
  6. Biochemical identification of the neutral endopeptidase family member responsible for the catabolism of amyloid beta peptide in the brain.
  7. Cholesterol modulates the membrane-disordering effects of beta-amyloid peptides in the hippocampus: specific changes in Alzheimer's disease.
  8. p35/cdk5 binds and phosphorylates beta-catenin and regulates beta-catenin/presenilin-1 interaction.
  9. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease.
  10. Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia.
  11. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients.
  12. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.
  13. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease.
  14. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees.
  15. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people.